Skip to main content

Table 1 Summary of positive phase 3 clinical trials of angiogenic inhibitors in patients with advanced hepatocellular carcinoma (HCC)

From: Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Molecules Trial N Population mOS mPFS ORR DCR Comments
Sorafenib SHARP [18] 602 First-line
Versus placebo
10.7 m 5.5 m 2% 43%  
  ASIAPACIFIC [19] 226 First-line
Versus placebo
6.5 m 2.8 m 3.3% 35.3%  
Lenvatinib REFLECT [20] 954 First-line
Versus sorafenib
13.6 m 8.9 m 24.1, 1%CR 75.5%  
Regorafenib RESORCE [21] 573 Second-line
Versus placebo
10.6 m 3.2 m 11% 65% Exclusion of patients previously intolerant to sorafenib
Cabozantinib CELESTIAL [22] 707 Second or third-line
Versus placebo
10.2 m 5.2 m 4% 64% Inclusion of patients previously intolerant to sorafenib
Ramucirumab REACH-2 (35) 292 Second-line
Versus placebo
8.5 m 2.8 m 4.6% 59.9% Inclusion of patients with poor prognosis based on high alpha-foeto-protein levels
  1. CR complete response; DCR disease control rate; m months; mOS median overall survival; mPFS median progression-free-survival; N number of randomized patients; ORR objective response rate